{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T01:52:09Z","timestamp":1788054729175,"version":"build-2784847793"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013858","name":"Cambridge Philosophical Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011889","name":"Diamond Light Source","doi-asserted-by":"publisher","award":["SM36941"],"award-info":[{"award-number":["SM36941"]}],"id":[{"id":"10.13039\/100011889","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011889","name":"Diamond Light Source","doi-asserted-by":"publisher","award":["SM38189"],"award-info":[{"award-number":["SM38189"]}],"id":[{"id":"10.13039\/100011889","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoiotech.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immuno-Oncology and Technology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.iotech.2025.101533","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T10:15:12Z","timestamp":1763374512000},"page":"101533","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Ligand-receptor interactions of V-domain Ig-containing suppressor of T cell activation and programmed death-1 suppress the anticancer activities of T cells"],"prefix":"10.1016","volume":"28","author":[{"given":"M.","family":"Abooali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.M.","family":"Yasinska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8743-7795","authenticated-orcid":false,"given":"S.","family":"Schlichtner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6207-6631","authenticated-orcid":false,"given":"R.","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4667-6423","authenticated-orcid":false,"given":"G.","family":"Siligardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6081-874X","authenticated-orcid":false,"given":"T.-M.","family":"Gianga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.M.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Cholewa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0537-228X","authenticated-orcid":false,"given":"B.F.","family":"Gibbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Fasler-Kan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.V.","family":"Sumbayev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.iotech.2025.101533_bib1","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1158\/0008-5472.CAN-13-1504","article-title":"VISTA is an immune checkpoint molecule for human T cells","volume":"74","author":"Lines","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.iotech.2025.101533_bib2","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1158\/2326-6066.CIR-14-0072","article-title":"VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy","volume":"2","author":"Lines","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.iotech.2025.101533_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217581","article-title":"Intracellular and extracellular activities of V-domain Ig-containing suppressor of T cell activation (VISTA) modulated by immunosuppressive factors of tumour microenvironment","volume":"616","author":"Abooali","year":"2025","journal-title":"Cancer Lett"},{"key":"10.1016\/j.iotech.2025.101533_bib4","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/s12935-023-03116-0","article-title":"VISTA and its ligands: the next generation of promising therapeutic targets in immunotherapy","volume":"23","author":"Shekari","year":"2023","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.iotech.2025.101533_bib5","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/imm.13001","article-title":"VSIG-3 as a ligand of VISTA inhibits human T-cell function","volume":"156","author":"Wang","year":"2019","journal-title":"Immunology"},{"key":"10.1016\/j.iotech.2025.101533_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.580557","article-title":"Ligand-Receptor interactions of Galectin-9 and VISTA suppress human T lymphocyte cytotoxic activity","volume":"11","author":"Yasinska","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.iotech.2025.101533_bib7","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41586-019-1674-5","article-title":"VISTA is an acidic pH-selective ligand for PSGL-1","volume":"574","author":"Johnston","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.iotech.2025.101533_bib8","doi-asserted-by":"crossref","first-page":"6682","DOI":"10.1073\/pnas.1420370112","article-title":"Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses","volume":"112","author":"Liu","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.iotech.2025.101533_bib9","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005714","article-title":"T lymphocytes induce human cancer cells derived from solid malignant tumors to secrete galectin-9 which facilitates immunosuppression in cooperation with other immune checkpoint proteins","volume":"11","author":"Schlichtner","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.iotech.2025.101533_bib10","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1907059","article-title":"VISTA and PD-L1 synergistically predict poor prognosis in patients with extranodal natural killer\/T-cell lymphoma","volume":"10","author":"He","year":"2021","journal-title":"OncoImmunology"},{"key":"10.1016\/j.iotech.2025.101533_bib11","article-title":"Editorial: Pathological reactions of cytotoxic lymphoid cells as universal therapeutic targets in cancer and autoimmune disease","volume":"10","author":"Sumbayev","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.iotech.2025.101533_bib12","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2023.2244330","article-title":"L-Kynurenine participates in cancer immune evasion by downregulating hypoxic signaling in T lymphocytes","volume":"12","author":"Schlichtner","year":"2023","journal-title":"OncoImmunology"},{"key":"10.1016\/j.iotech.2025.101533_bib13","doi-asserted-by":"crossref","first-page":"6307","DOI":"10.1038\/srep06307","article-title":"Crucial involvement of xanthine oxidase in the intracellular signalling networks associated with human myeloid cell function","volume":"4","author":"Abooali","year":"2014","journal-title":"Sci Rep"},{"key":"10.1016\/j.iotech.2025.101533_bib14","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1107\/S1600577514028161","article-title":"CDApps: integrated software for experimental planning and data processing at beamline B23, Diamond Light Source","volume":"22","author":"Hussain","year":"2015","journal-title":"J Synchrotron Radiat"},{"key":"10.1016\/j.iotech.2025.101533_bib15","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1107\/S0909049511038982","article-title":"Circular dichroism beamline B23 at the Diamond Light Source","volume":"19","author":"Hussain","year":"2012","journal-title":"J Synchrotron Radiat"},{"key":"10.1016\/j.iotech.2025.101533_bib16","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/978-1-4939-2230-7_14","article-title":"CD spectroscopy: an essential tool for quality control of protein folding","volume":"1261","author":"Siligardi","year":"2015","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.iotech.2025.101533_bib17","doi-asserted-by":"crossref","first-page":"33823","DOI":"10.18632\/oncotarget.5257","article-title":"Differential expression and biochemical activity of the immune receptor Tim-3 in healthy and malignant human myeloid cells","volume":"6","author":"Gon\u00e7alves Silva","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.iotech.2025.101533_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1599352","article-title":"Wuhan strain of SARS-CoV-2 triggers activation of immune evasion machinery similar to the one operated by cancer cells","volume":"16","author":"Abooali","year":"2025","journal-title":"Front. Immunol"},{"key":"10.1016\/j.iotech.2025.101533_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0140694","article-title":"TIM-3 suppresses anti-CD3\/CD28-induced TCR activation and IL-2 expression through the NFAT signaling pathway","volume":"10","author":"Tomkowicz","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.iotech.2025.101533_bib20","doi-asserted-by":"crossref","first-page":"14179","DOI":"10.1016\/S0021-9258(18)98663-1","article-title":"Activation of interleukin-2 gene transcription via the T-cell surface molecule CD28 is mediated through an NF-kB-like response element","volume":"266","author":"Verweij","year":"1991","journal-title":"J Biol Chem"},{"key":"10.1016\/j.iotech.2025.101533_bib21","doi-asserted-by":"crossref","first-page":"624","DOI":"10.3389\/fimmu.2020.00624","article-title":"Regulation of T helper cell fate by TCR signal strength","volume":"11","author":"Bhattacharyya","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.iotech.2025.101533_bib22","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.bbrc.2009.01.105","article-title":"Involvement of PKC alpha in PMA-induced facilitation of exocytosis and vesicle fusion in PC12 cells","volume":"380","author":"Xue","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"issue":"9","key":"10.1016\/j.iotech.2025.101533_bib23","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.tips.2015.06.005","article-title":"New immunotherapies targeting the PD-1 pathway","volume":"36","author":"Chinai","year":"2015","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.iotech.2025.101533_bib24","doi-asserted-by":"crossref","first-page":"11771","DOI":"10.1074\/jbc.M112.448126","article-title":"Structure and interactions of the human programmed cell death 1 receptor","volume":"288","author":"Cheng","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1016\/j.iotech.2025.101533_bib25","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.str.2017.06.011","article-title":"Structural biology of the immune checkpoint receptor PD-1 and its ligands PD-L1\/PD-L2","volume":"25","author":"Zak","year":"2017","journal-title":"Structure"}],"container-title":["Immuno-Oncology and Technology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590018825004939?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590018825004939?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T04:37:42Z","timestamp":1778906262000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590018825004939"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":25,"alternative-id":["S2590018825004939"],"URL":"https:\/\/doi.org\/10.1016\/j.iotech.2025.101533","relation":{},"ISSN":["2590-0188"],"issn-type":[{"value":"2590-0188","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ligand-receptor interactions of V-domain Ig-containing suppressor of T cell activation and programmed death-1 suppress the anticancer activities of T cells","name":"articletitle","label":"Article Title"},{"value":"Immuno-Oncology and Technology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iotech.2025.101533","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"101533"}}